Even though AR expression levels are relatively low in some cell lines such as U87MG and Ln229, they were still susceptible to AR antagonists with IC50s of enzalutamide and bicalutamide being ~40 and 80–160 μM, respectively, for all tested human GBM cell lines. The gene discussed is AR; the disease is glioblastoma.